FDG-PET as a Prognostic Factor in High-grade Astrocytoma
- 1 September 2000
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 49 (2) , 157-163
Abstract
Background: The prognostic value of the metabolic status of cerebral gliomas determined by positron emission tomography with [18F]-fluoro-deoxy-D-glucose (FDG-PET) has been established in populations with a mixture of grades 2, 3 and 4 gliomas, but remains uncertain when only malignant gliomas are considered (grade 3 and 4). Methods: FDG-PET performed in 30 patients with anaplastic astrocytoma (grade III) and 61 patients with glioblastoma (grade 4) were classified according to a metabolic grading. The uptake of FDG was lower in the tumor compared to white matter (WM) in grade 1 (4 glioblastoma, 4 anaplastic astrocytoma), it was intermediate between WM and cortex in grade 2 (20 glioblastoma, 22 anaplastic astrocytoma), and it was superior to cortex in grade 3 (38 glioblastoma, 4 anaplastic astrocytoma). Results: Kaplan–Meier survival curves were similar in patient with grades 1 and 2, but were significantly worse (p = 0.007) in grade 3. In multivariate analysis considering age, pathological grade (anaplastic astrocytoma versus glioblastoma), and metabolic grades, the metabolic grade did not appear to be an independent prognostic factor. When anaplastic astrocytomas and glioblastomas were considered separately, metabolic grade is of predictive value only in the group of glioblastomas. Conclusion: In malignant gliomas, metabolic grading determined by FDG-PET was not superior to the pathological grading for survival prediction. Still, it remains of predictive value when applied to malignant gliomas histologically classified as glioblastoma.Keywords
This publication has 16 references indexed in Scilit:
- Prognostic Value of Positron Emission Tomography with [18F]Fluoro-2-deoxy-D-glucose in the Low-grade GliomaNeurosurgery, 1996
- Regional glucose metabolism and histopathology of gliomas: A study based on positron emission tomography-guided stereotactic biopsyCancer, 1996
- Acute effect of carmustine on glucose metabolism in brain and glioblastomaCancer, 1994
- The New WHO Classification of Brain TumoursBrain Pathology, 1993
- Positron Emission Tomography-Guided Stereotactic Brain BiopsyNeurosurgery, 1992
- Positron emission tomography in patients with glioma a predictor of prognosisCancer, 1988
- Positron Emission Tomography Using [18F] Fluorodeoxyglucose in Brain Tumors A Powerful Diagnostic and Prognostic ToolInvestigative Radiology, 1987
- Prediction of survival in glioma patients by means of positron emission tomographyJournal of Neurosurgery, 1985
- Issues in the in vivo measurement of glucose metabolism of human central nervous system tumorsAnnals of Neurology, 1984
- Glucose utilization of cerebral gliomas measured by [ 18 F] fluorodeoxyglucose and positron emission tomographyNeurology, 1982